Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals USA, Inc.
1:17-cv-00393
Overview
Parties
Defendant
Teva Pharmaceuticals USA, Inc. Operating Company
Represented By
0 Attorneys ListedPlaintiff
Novartis Pharmaceuticals Corporation Operating Company
Represented By
0 Attorneys ListedCourt & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 11 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | Asserted Patent | View Official Patent → |
| π¬π§ United Kingdom | United Kingdom Counterpart | View Official Patent → | |
| π¬π§ United Kingdom | United Kingdom Counterpart | View Official Patent → | |
| π¬π§ United Kingdom | United Kingdom Counterpart | View Official Patent → | |
| π¬π§ United Kingdom | United Kingdom Counterpart | View Official Patent → | |
| π¬π§ United Kingdom | United Kingdom Counterpart | View Official Patent → | |
| π¬π§ United Kingdom | United Kingdom Counterpart | View Official Patent → | |
| πͺπΊ European Patent Office (UPC States) | European Counterpart (EP) | View Official Patent → | |
| π¬π§ United Kingdom | United Kingdom Counterpart | View Official Patent → | |
| π PCT International (WIPO) | PCT World Application | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
Hikma Pharmaceuticals PLC v. Novartis Pharmaceuticals Corporation
Breckenridge Pharmaceutial, Inc. v. Novartis Pharmaceuticals Corporation
West-Ward Pharmaceuticals International Limited v. Novartis AG
Argentum Pharmaceuticals LLC et al. v. Novartis AG
Par Pharmaceutical, Inc. et al. v. Novartis AG
Roxane Laboratories, Inc. et al. v. Novartis AG
Patents Involved
There are 4 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US9006224
Neuroendocrine tumor treatment
|
Filed: 2006-11-20
Issued: 2015-04-14
|
Active (1.6 yrs remaining)
+589d PTA
Expires: 2028-07-01
|
|
|
US8410131
Cancer treatment
|
Filed: 2002-02-18
Issued: 2013-04-02
|
Expired (Term Ended)
+1352d PTA
Expires: 2025-11-01
|
|
|
US8778962
Treatment of solid tumors with rapamycin derivatives
|
Filed: 2012-07-11
Issued: 2014-07-15
|
Active (5.6 yrs remaining)
Expires: 2032-07-11
|
|
|
US8436010
Treatment of solid tumors with rapamycin derivatives
|
Filed: 2012-02-23
Issued: 2013-05-07
|
Expired (Term Ended)
Expires: 2022-02-22
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term; injunctive relief viable.
High PTA (+589 days) / In re Cellect scrutiny applies.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).